ArticleFood chemistry: X2025
Cashew nut oligopeptide inhibits mast cell degranulation by suppressing activation of the NF-Κb signalling pathway.
Article in Food chemistry: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial Special issue:Food chemistry: X · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to isolate oligopeptides with anti-allergic properties from cashew nuts. Cashew nut protein was extracted using subcritical water extraction. Subsequently, cashew nut oligopeptides (COPs) were obtained via a two-step enzymatic hydrolysis involving alkaline proteinase and bromelain. Mass spectrometry analysis identified a specific COP with the sequence Ile-Ile-Ala-Ile-Pro-Ala-Gly-Val-Ala-His. This COP was synthesised to investigate its impact on preventing degranulation. Analysis revealed that COP effectively inhibited the release and production of proinflammatory mediators, including tumour necrosis factor-α, interleukin-6, histamine and β-hexosaminidase and influx of extracellular calcium ions. Furthermore, COP significantly suppressed degranulation and inflammatory responses by inhibiting activation of nuclear factor kappa B signalling pathway in allergic mast cells. These findings suggest that COP possesses strong anti-allergic effects by specifically targeting mast cells degranulation. This s highlights COP's therapeutic potential against allergic inflammatory disorders, and its promising role in treating allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.